ASMB Stock Overview
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Assembly Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.21 |
| 52 Week High | US$19.93 |
| 52 Week Low | US$9.12 |
| Beta | 0.56 |
| 1 Month Change | 1.13% |
| 3 Month Change | -6.46% |
| 1 Year Change | 60.44% |
| 3 Year Change | -44.16% |
| 5 Year Change | -93.95% |
| Change since IPO | -95.98% |
Recent News & Updates
Recent updates
Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers
Nov 13
Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely
Aug 17Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?
Feb 27We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Nov 09Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end
Oct 05Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce
Jul 20We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jun 08We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jan 11We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Sep 03Assembly Biosciences announces resignation of CFO
Jun 02Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook
Mar 24Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares
Feb 05We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
Dec 14
Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators
Nov 16Assembly Biosciences EPS beats by $0.69, beats on revenue
Nov 05Shareholder Returns
| ASMB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.1% | -3.6% | -2.4% |
| 1Y | 60.4% | -2.6% | 23.4% |
Return vs Industry: ASMB exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ASMB exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| ASMB volatility | |
|---|---|
| ASMB Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ASMB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ASMB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 65 | Jason Okazaki | www.assemblybio.com |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
Assembly Biosciences, Inc. Fundamentals Summary
| ASMB fundamental statistics | |
|---|---|
| Market cap | US$96.68m |
| Earnings (TTM) | -US$40.80m |
| Revenue (TTM) | US$28.33m |
3.4x
P/S Ratio-2.4x
P/E RatioIs ASMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASMB income statement (TTM) | |
|---|---|
| Revenue | US$28.33m |
| Cost of Revenue | US$52.66m |
| Gross Profit | -US$24.33m |
| Other Expenses | US$16.47m |
| Earnings | -US$40.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.42 |
| Gross Margin | -85.90% |
| Net Profit Margin | -144.05% |
| Debt/Equity Ratio | 0% |
How did ASMB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Assembly Biosciences, Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Raymond Deacon | Brean Capital |
| Madhu Kumar | B. Riley Securities, Inc. |